Comparison of Ferric Sodium EDTA in Combination with Vitamin C, Folic Acid, Copper Gluconate, Zinc Gluconate, and Selenomethionine as Therapeutic Option for Chronic Kidney Disease Patients with Improvement in Inflammatory Status

• Published in: Nutrients 2022-05, Vol.14 (10), p.2116
• Main Authors: Giliberti, Antonella, Curcio, Annalisa, Marchitto, Nicola, Di Lullo, Luca, Paolozzi, Fulvia, Nano, Fabiana, Pironti, Michele, Raimondi, Gianfranco
• Format: Article
• Language: English
• Subjects: Acids; Aged; Anemia; Anemia, Iron-Deficiency; Antioxidants - therapeutic use; Ascorbic acid; Ascorbic Acid - therapeutic use; Blood circulation; C-reactive protein; Chronic illnesses; chronic kidney disease; Complications; Copper; Edetic acid; Edetic Acid - therapeutic use; Ethylenediaminetetraacetic acids; ferric sodium EDTA; Ferritin; Ferrous sulfate; Folic acid; Folic Acid - therapeutic use; Gluconates; Hemodialysis; Hemoglobin; Hepcidin; Hepcidins; Hospitals; Humans; Inflammation; Iron; iron deficiency anemia; Iron sulfates; Kidney diseases; Kidneys; Laboratories; Liver; Metabolism; Nephrology; Nutrient deficiency; Patients; Quality of Life; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - drug therapy; Selenomethionine; Selenomethionine - therapeutic use; Sodium; Statistical analysis; Sulfates; Transferrin; Transferrins; Vitamin B; Vitamin C; Vitamins - therapeutic use; Womens health; Zinc
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu14102116

Anemia is one of the most frequent and earliest complications of chronic kidney disease (CKD), which impacts a patient’s quality of life and increases the risk of adverse clinical outcomes. Patients’ inflammatory status is strictly related to the occurrence of functional iron deficiency anemia (IDA) because this causes an increase in hepcidin levels with the consequent inhibition of iron absorption and release from cellular stores into blood circulation. The aim of this study was to evaluate the use of the new oral formulation based on ferric sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate, and selenomethionine (Ferachel Forte®) in patients with moderate CKD and functional IDA, analyzing the inflammatory status in addition to iron blood parameters, in comparison with oral ferrous sulfate and liposomal iron therapies. Sixty-two elderly patients were randomly allocated to one of the following oral treatments for 6 months: ferrous sulfate (Group 1; N = 20), ferric sodium EDTA in combination (Group 2; N = 22), and ferric liposomal formulation (Group 3; N = 20). The evaluated parameters included iron profile parameters of hemoglobin (Hb), sideremia, ferritin, transferrin saturation, C-reactive protein (CRP), and hepcidin. The results showed that in Group 1, there were no improvements. In Group 2, there were statistically significant (p < 0.001) improvements in all evaluated parameters. Finally, in Group 3, there were significant improvements in all evaluated parameters except for hepcidin, which was less than that of Group 2 patients. In conclusion, the findings showed the superior efficacy of the formulation based on ferric sodium EDTA over the other oral iron sources, and that this formulation can contribute to reducing the systemic inflammatory status in patients with CKD.